Novartis, Cephalon Disease-Modifying Parkinson's Drugs Near Late-Stage Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis' TCH-346 is slated to enter Phase III in the second half of the year; Cephalon/Lundbeck's CEP-1347 is in Phase II/III. Both drugs claim inhibition of neuronal cell death as the primary mechanism, but will need long-term trials for disease-modification claim.
You may also be interested in...
Pharmos Dexanabinol (Correction)
Pharmos' Phase III trial for its cannabinoid dexanabinol in traumatic brain injury has completed projected enrollment of about 860 patients in the U.S. and other countries; results are expected by year-end.FDA placed the NMDA antagonist on fast-track status in September 2003. Dexanabinol has never been in clinical development for Parkinson's disease or Alzheimer's disease, as suggested in a story in "The Pink Sheet" DAILY (1"The Pink Sheet" DAILY, March 19, 2004)
Pharmos Dexanabinol (Correction)
Pharmos' Phase III trial for its cannabinoid dexanabinol in traumatic brain injury has completed projected enrollment of about 860 patients in the U.S. and other countries; results are expected by year-end.FDA placed the NMDA antagonist on fast-track status in September 2003. Dexanabinol has never been in clinical development for Parkinson's disease or Alzheimer's disease, as suggested in a story in "The Pink Sheet" DAILY (1"The Pink Sheet" DAILY, March 19, 2004)
Aventis/Novartis Merger Would Infuse New Blood Into Novartis' Cardiology R&D
The combined cardiovascular portfolio would be a strategic fit since Aventis has focused more on acute indications, while Novartis has targeted chronic conditions. Oncology would be largest therapeutic area.